FKC - East Houma is a medicare approved dialysis facility center in Houma, Louisiana and it has 13 dialysis stations. It is located in Terrebonne county at 707 Grand Caillou Rd, Houma, LA, 70363. You can reach out to the office of FKC - East Houma at (985) 262-4143. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FKC - East Houma has the following ownership type - Profit. It was first certified by medicare in March, 2011. The medicare id for this facility is 192708 and it accepts patients under medicare ESRD program.
| Name | FKC - East Houma |
|---|---|
| Location | 707 Grand Caillou Rd, Houma, Louisiana |
| No. of Dialysis Stations | 13 |
| Medicare ID | 192708 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 707 Grand Caillou Rd, Houma, Louisiana, 70363 | |
| (985) 262-4143 | |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
| NPI Number | 1215475868 |
| Organization Name | Fresenius Kidney Care East Houma |
| Doing Business As | Bio-medical Applications Of Louisiana, Llc |
| Address | 707 Grand Caillou Rd Houma, Louisiana, 70363 |
| Phone Number | (985) 262-4143 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
| NPI Number | 1265743702 |
| Organization Name | Rrc Houma |
| Doing Business As | Reliant Renal Care Louisiana Llc |
| Address | 707 Grand Caillou Rd Houma, Louisiana, 70363 |
| Phone Number | (610) 892-4700 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 55 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 16 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 64 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 566 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
| Adult patients getting regular peritoneal dialysis at the center | 30 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 291 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 89 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FKC - East Houma with elevated calcium levels.
| Patients with hypercalcemia | 99 |
| Hypercalcemia patient months | 954 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 103 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 24 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 26 |
| Patients with Serumphosphor greater than 7 mg/dL | 18 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 66 |
| Patient months included in arterial venous fistula and catheter summaries | 547 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 79 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 97 |
| Hospitalization Rate in facility | 128 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 252.3 |
| Hospitalization Rate: Lower Confidence Limit | 72 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at FKC - East Houma were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 30 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 46.4 |
| Readmission Rate: Lower Confidence Limit | 17.3 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FKC - East Houma get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .8 (As Expected) |
| SIR: Upper Confidence Limit | 2.16 |
| SIR: Lower Confidence Limit | .2 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FKC - East Houma's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 91 |
| Transfusion Rate in facility | 28.1 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 72.2 |
| Transfusion Rate: Lower Confidence Limit | 12.3 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
The rate of mortality show you whether patients who were being treated regularly at FKC - East Houma lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 455 |
| Mortality Rate in facility | 25.2 (Worse than Expected) |
| Mortality Rate: Upper Confidence Limit | 32.9 |
| Mortality Rate: Lower Confidence Limit | 18.9 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago
Fmcna - North Houma Dialysis Location: 144 War Horse Pl, Houma, Louisiana, 70360 Phone: (985) 876-6304 |
News Archive
The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Imaging techniques are increasingly at the forefront of progress in science and technology.
The frequency and nature of bacteria in the urinary tract differs significantly between healthy women and those with urge incontinence, a US study demonstrates.
› Verified 8 days ago